Ajax Therapeutics

Ajax Therapeutics is pleased to announce that the first patient has been enrolled and dosed on clinical trial AJX-101, a first-in-human study of AJ1-11095 in patients with myelofibrosis who have been failed by at least 1 JAK inhibitor and who continue to have splenomegaly and burdensome symptoms. AJ1-11095 is the first type II JAK2 inhibitor to enter clinical trials. In contrast to existing type I JAK2 inhibitors, which bind the JAK2 kinase in its active "DFG-in" conformation, AJ1-11095 was designed (using structure-based drug design and computational methods, in collaboration with Schrödinger) to bind JAK2 in the enzyme's inactive "DFG-out" conformation. In preclinical models of myeloproliferative neoplasms, AJ1-11095 overcomes a primary mechanism of JAK inhibitor resistance/persistence, and achieves disease control and mutant allele burden reduction. In May 2024, Ajax announced US FDA clearance of its IND application to commence a phase I trial of AJ1-11095, as well as additional funding to support the company's developmental programs. https://lnkd.in/e_t9Y8cm

Next stop->clinic for AJ-101095! (please note my COI as co-founder)

Financial Times article today about Ajax Therapeutics $95M Series C raise in support of AJ1-11095 clinical development: https://lnkd.in/gMPNt7U3

Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis https://lnkd.in/gcC35a5E

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic – Financing led by Goldman Sachs Alternatives with participation by new investors Lilly, Vivo Capital, RA Capital Management, Point72 and existing investors –  – AJ1-11095 will be the first Type II JAK2 Inhibitor to enter the clinic; Phase 1 study in myelofibrosis expected to begin in 2H 2024 – https://lnkd.in/g5dJfqRM